As previously reported, Raymond James upgraded Editas Medicine to Outperform from Market Perform with a $17 price target. The data update at EHA suggests that EDIT-301 is working consistently and is “an important de-risking dataset” given that EDIT-301 uses a novel Cas enzyme and cuts a novel site, the analyst tells investors. It “already looks like EDIT-301 has potential to be a ‘functional cure,’ like lovo-cel and exa-cel,” and early Hb signals leave open the possibility of a superior data profile, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EDIT:
- Biotech Alert: Searches spiking for these stocks today
- Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial
- Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
- Editas Medicine Reports Inducement Grant to New Chief Financial Officer
- Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer